Introduction
Breast cancer is the most commonly diagnosed cancer and the second most common cause of cancer death in women in the USA. [1] [2] [3] The human epidermal growth factor receptor 2 (HER2) oncogene encodes for a 185 kD transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. 4 It belongs to the human EGFR family including HER1, HER2, HER3, and HER4 that control breast cancer cell proliferation, migration, and invasion. 5 Amplification of HER2 is observed in approximately 20% of human breast cancers. [6] [7] [8] HER2-positive breast cancer is associated with increased rates of metastasis, reduced time to relapse, poorer prognosis, and higher mortality. 6, 9 Development of HER2-targeted immunotherapeutics such as HER2-specific monoclonal antibodies trastuzumab and lapatinib has greatly improved therapeutic outcome. 10 Trastuzumab is remarkably effective both as monotherapy and in combination with cytotoxic chemotherapy in patients with HER2-positive metastatic breast cancer. However, most patients sooner or later develop resistance to trastuzumab during trastuzumab treatment, 11, 12 warranting the development of other effective HER2-targeted therapies.
Three signals in CD8
+ T cell response CD8 + cytotoxic T lymphocytes (CTLs) are responsible for adaptive immune responses against tumor. After antigen presentation to naïve CD8 + T cells by antigen-presenting cells, such as dendritic cells (DCs), CD8
+ T cells start to proliferate and become cytotoxic effectors capable of inducing cancer cell death via secreting cytokines (tumor necrosis factor-α and interferon-γ [IFN-γ]) and cytolytic granzyme-B. 13 There are three conventional signals submit your manuscript | www.dovepress.com
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Li et al participating in induction of CD8 + CTL immunity. The first signal is derived from the antigen peptide-presenting major histocompatibility complexes (pMHC-I) on DCs, which recognize the antigen-specific T-cell receptors (TCRs) on CD8 + T cells ( Figure 1A ). The second costimulatory signal is the interaction of DC's costimulatory CD80 molecules with CD28 ligands on CD8 + T cells ( Figure 1A ). The third signal represents the innate inflammatory cytokines such as IL-12 and IFN-α-stimulating CD8
+ T cells ( Figure 1A ). The first two signals are responsible for naïve CD8 + T-cell proliferation, while IL-12
and IFN-α are in charge of the development of CTL effector functions. 13 Apart from those signals, IL-15 secreted by DCs induces T-cell memory formation. 
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Novel eXO-T vaccine for HeR2-positive breast cancer of anti-HER2 vaccines to stimulate patient's own immune system against breast cancer. HER2-specific vaccines using HER2-specific peptides, proteins, DNA, or DCs have been developed, but mostly showing relatively limited antitumor effects. 16 Exosomes (EXOs) are small vesicles of 50-100 nm in diameter secreted by budding from the cellular membrane. 17 DC-released EXOs are enriched in immunological molecules important for DC's stimulatory machinery. 17 Similar to the previous adoptive engineered CD8 + T-cell therapy using active polyclonal CD8 + T cells engineered to express tumor-specific TCR, 18 we developed novel CD4 + T-cellbased (EXO-T) vaccines using active polyclonal CD4 + T cells armed with tumor-specific DC-released EXOs. [19] [20] [21] [22] [23] [24] [25] In the former one, polyclonal CD8 + T cells are genetically engineered to express tumor-specific TCRs containing signaling domain of CD3 zeta-chain or to express chimeric antigen receptor containing single-chain Fv fused to signaling domain of T-cell costimulatory molecules such as 41BB leading to the currently well-known chimeric antigen receptor-T therapy. 26 In the latter one, EXO-T vaccines prepared by simply incubation of ConA-stimulated polyclonal CD4
+ T cells with antigen-specific DC-released EXOs. The polyclonal CD4
+ T cells took up antigen-specific DC-released EXOs via interaction of exosomal CD54 with T cell lymphocyte function-associated antigen 1, leading to the expression of exosomal surface molecules (pMHC-I and CD80) on CD4
+ T cells via vesicle internalization/recycling and direct membrane fusion. 19 As a result, the polyclonal CD4 + T cells phenotypically armed with antigen-specific exosomal pMHC-I complexes and exosomal CD80 molecule became antigen-specific EXO-T vaccines.
19-25
Compared with vaccination of DCs presenting the three conventional signals, EXO-T vaccines stimulate CD8
+ T-cell responses via three distinct signals namely 1) acquired exosomal pMHC-I, 2) acquired exosomal CD80 and CD4 + T cell CD40L, and 3) CD4 + T cell IL-2 ( Figure 1B ). EXO-T vaccines have been found to stimulate potent CD4 + T-cellindependent CTL responses [19] [20] [21] [22] [23] [24] [25] and to promote CTL memory via CD4 + T cell CD40L signaling.
CD8
+ CTL exhaustion with overexpression of inhibitory molecules such as PD-1, Tim-3, and LAG-3 and with functional deficiency in the production of effector cytokine IFN-γ and effector cytolytic granzyme-B is a state of dysfunction that commonly occurs during cancer and infection diseases, which leads to failure in reducing viral or tumor load. 27 We demonstrated that EXO-T vaccine was able to convert CTL exhaustion in chronic infection via CD4 + T cell CD40L signaling-induced activation of mTORC1 pathway, leading to CTL proliferation, IFN-γ production, and rescuing CTL cytotoxic effect. 21 Because tumor-specific effector CTLs that undergo tumor tolerogenic microenvironment also become terminally differentiated into exhausted CTLs without any antitumor properties, 28 our novel EXO-T vaccine may thus be able to exert its conversional effect on exhausted CTLs within tumors ( Figure 1C ).
HER2-Texo vaccine
We have recently developed Neu-specific (the rat's form of human HER2) or HER2-specific EXO-T vaccines (Neu-Texo and HER2-Texo) using active polyclonal CD4 + T cells with uptake of Neu-or HER2-specific DC-released EXOs. 22 We demonstrated that Neu-specific EXO-T vaccine stimulated Neu-specific CTL responses against Neu-expressing breast cancer Tg1-1 in transgenic FVBneuN mice, while HER2-specific EXO-T vaccine stimulated HER2-specific immunity against HER2/HLA-A2-expressing BL6-10 A2/HER2 melanoma in double transgenic HER2/HLA-A2 mice with HER2-specific self-immune tolerance. 22 In addition, HER2-specific EXO-T-stimulated CTLs also showed potent therapeutic effect against both HER2-positive breast cancer T47D and trastuzumab-resistant HER2-positive breast cancer BT474 in athymic nude mice. 22 Heterologous DNA vaccines composed of fused cDNA fragments encoding chimeric NH2-terminal human HER2 and COOH-terminal rat Neu sequences have been reported to stimulate stronger antibody responses and protective antitumor immunity than either HER2 or Neu DNA vaccine in transgenic mice with HER2-specific self-immune tolerance. 29, 30 These findings prompted us to have a hypothesis that heterologous HER2/Neu-specific T cell vaccine may induce more effective anti-HER2 CTL responses. To test this hypothesis, we construct an adenoviral vector (AdV HER2/Neu ) expressing a fused cDNA fragment (Hu/Rt HER2/Neu) encoding chimeric NH2-terminal human (Hu) HER2 and COOH-terminal rat (Rt) Neu sequence by recombinant DNA technology. 31 Based on AdV HER2/Neu , we further generated heterologous HuRt HER2/Neu-specific EXO-T vaccine (HuRt-Texo) using polyclonal CD4 + T cells with uptake of AdV HER2/Neu -transfected DC-release EXOs. 31 We demonstrated that heterologous HuRt-Texo vaccine, in comparison with homologous HER2-Texo one, more strongly stimulated both HER-2-specific antibody and CTL responses leading to complete inhibition of growth of established lung metastasis of HER2-expressing 4T1 HER2 breast cancer in BALB/c mice and complete protection of transgenic HLA-A2/HER2 mice from growth of HLA-A2/HER2-expressing BL6-10 A2/HER2 melanoma in double transgenic HER2/HLA-A2 mice. 31 In addition, HuRt-T EXO -stimulated CTLs are also able to 
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Li et al eradicate established trastuzumab-resistant BT474 breast cancer in athymic nude mice. 31 The long-term goal is to develop human therapeutic HER2/Neu-specific EXO-T vaccine using autologous polyclonal T cells with uptake of HER2/Neu-specific autologous DC (DC HER2/Neu )-released EXOs as a new novel personalized vaccine for breast cancer. 32 The human autologous DCs derived from peripheral blood monocytes activated in culture medium by granulocyte-macrophage colony-stimulating factor, IL-4, and tumor necrosis factor-α 33 followed by infection with HER2/Neu-specific adenoviral vector (AdV HER2/Neu ) to form DC HER2/Neu .
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Conclusion
Taken together, our data indicate that HER2-specific EXO-T vaccine circumventing HER2 tolerance may provide a new therapeutic alternative for trastuzumab-resistant breast cancer patients with HER2-specific self-immune tolerance. Because many other human cancer antigens were also identified including α-fetal protein, carcinoembryonic antigen, CA125, CA19-9, and prostate-specific antigen in various types of cancer, 34 novel EXO-T vaccines similarly generated by arming polyclonal CD4 + T cells with different tumor antigenspecific EXOs are thus likely to become a useful therapeutic strategy to assist in the treatment of various cancers.
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